Wegovy's New Triple-Dose Variant Set for UK Release

Wegovy, a weight loss medication manufactured by Novo Nordisk, is set to introduce a new triple-strength variant in the UK, which will be available within the next six weeks. Currently, the highest accessible dose is 2.4 milligrams, but the new formulation will deliver 7.2 milligrams of semaglutide, administered once a week. This change simplifies the previous regimen, which required injections three times a week.

LADbible

The Medicines and Healthcare products Regulatory Agency (MHRA) approved the new dosage following a comprehensive trial involving over 1,000 obese participants over a 72-week period. Results indicated that participants using the 7.2 mg dose experienced an average weight loss of 20.7 percent, compared to just 2.4 percent for those on a placebo. Notably, one-third of the trial participants lost at least 25 percent of their body weight. However, the trials also reported common side effects, including gastrointestinal issues, constipation, and nausea.

LADbible

Sebnem Avsar Tuna, the general manager of Novo Nordisk UK, expressed support for the MHRA's decision, stating, "The approval of this new single-dose device provides an additional administration option for people in the UK who are prescribed the 7.2 mg once weekly maintenance dose of Wegovy." The MHRA has committed to ongoing safety reviews of Wegovy, encouraging users to report any adverse effects through the Yellow Card scheme.

LADbible

While the introduction of the new Wegovy variant is anticipated positively, concerns remain regarding the side effects experienced during clinical trials. The MHRA has acknowledged these issues, emphasizing the importance of monitoring and reporting any adverse reactions. Critics may argue that the potential for gastrointestinal side effects could deter some patients from using the medication.

LADbible

As Wegovy prepares for its UK launch, healthcare professionals and partners will collaborate to ensure a smooth introduction of the new dosage in line with local prescribing arrangements. The ongoing review by the MHRA will also play a crucial role in assessing the long-term safety and efficacy of the new formulation.

LADbible

• “The approval of this new single-dose device provides an additional administration option for people in the UK who are prescribed the 7.2 mg once weekly maintenance dose of Wegovy. We welcome the MHRA's decision and will continue to work with healthcare professionals and partners to support its introduction in line with local prescribing arrangements.” — Sebnem Avsar Tuna, General Manager, Novo Nordisk UK

LADbible

• “Anyone who suspects they are having a side effect from this medicine are encouraged to talk to their doctor, pharmacist or nurse and report it directly to the Yellow Card scheme, either through the website or by searching the Google Play or Apple App stores for MHRA Yellow Card,” — MHRA Statement

LADbible